The FOP Registry: A Global Observational Study of Fibrodysplasia Ossificans Progressiva

L. Adam Sherman1, Kin Cheung3, Mary Anne Fitspatrick1, Robert J. Pignolo2, Fredrick S. Kaplan3

International FOP Association1; Department of Medicine, Mayo Clinic School of Medicine, Mayo Clinic, Rochester, MN2
Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA3

Introduction

Fibrodysplasia Ossificans Progressiva (FOP) is an ultra-rare, progressive genetic disorder that has an estimated prevalence of 0.5-1.3 per million. FOP is characterized by the formation of extraskelatal bone (heterotopic ossification) usually beginning in early childhood, and ultimately leading to pain, muscle destruction, joint fusion, progressive immobilization, and premature death.

The International FOP Association (IFOPA), a global patient association, developed the FOP Registry in 2015 to establish a single repository of clinical data on people living with FOP. The Registry is guided by a clinical protocol and informed consent, which have been approved by a centralized ethics committee. The FOP Registry also has a governance structure, including a Medical Board of Advisors to guide its conduct. The FOP Registry, which now includes a patient and medical portal, will advance our understanding of FOP, enhance clinical care, and facilitate clinical trial designs.

Methodology

The FOP Registry is an international, voluntary, observational study that captures demographic, socioeconomic, and disease information directly from patients with FOP via a secure web-based tool and from physicians who are caring for these patients. No experimental intervention is involved.

The FOP Registry is open to any patient with FOP across the globe, regardless of age or genotype status. To encourage global participation, the FOP Registry is currently translated into 7 languages: English, French, German, Spanish, Portuguese, Italian and Russian. Before enrolling into the registry, participants must first sign an informed consent and/or assent for minors.

The FOP Registry collects data from two portals:

Patient Portal

The Patient Portal allows FOP patients and caregivers to enter information about themselves and their experience living with FOP directly into a web-based data collection tool. Data is collected at enrollment into the Registry and then every 6 months.

Physician Portal

The Physician Portal allows physicians to enter clinical data about patients under their care, which could include information on specific marketed therapies. Patient data in the Physician Portal will be linked by key identifiers to the corresponding patient data in the Patient Portal.

Results

As of March 2019, the FOP Registry had 336 participants, or approximately 42% of the world’s known FOP population, participating from 54 countries. Fifty-three (53%) percent of the current Registry participants are female, with a median age for all participants of 21 years (range = 0.4-78 years). The journey to a correct diagnosis took an average of 2 years after symptom onset at a median age of 3 years (range = 0.1 - 45 years). People with FOP are diagnosed earlier than prior generations, with a median age of diagnoses of 2 for individuals < 18 years, versus 8 for adults.

Baseline and Demographic Characteristics

- **Age**
  - Median: 21 yrs (18-78 yrs)

- **Type of FOP**
  - R206H mutation
  - Other

- **Gender**
  - Male
  - Female

Geneticists and Orthopedists are the two most common physician specialists providing a definitive diagnosis of FOP. Approximately one quarter of Registry participants first sought care from a pediatrician for their FOP symptoms, but only 8% of participants reported that a pediatrician provided their correct diagnosis. At enrollment, participants reported the most extra bone growth in the neck, upper back, lower back, shoulder, hip, jaw, and head. Heterotopic ossification resulted in a total loss of joint mobility, with the shoulder, upper back, and neck reported as the three most prevalent body regions.

As FOP is a progressive disease, there are differences in total loss of mobility between adults (>18 years) and children (<18 years), with the most pronounced differences in the shoulders, elbows, and hips. For example, 39.8% of adult participants reported a total loss of mobility due to heterotopic bone in either shoulder, while just 13.9% of children reported a total loss of mobility in this body region. Similar trends in total loss of mobility between adults and children are seen among other body locations, albeit at different magnitudes.

Conclusion

Patient registries have played a prominent role in helping to elucidate the natural history of rare diseases – knowledge that is critical in the design and conduct of clinical trials. Patient registries can empower rare disease communities to directly contribute to research. The FOP Registry is well on its way to helping the FOP community to achieve these ambitious and urgent goals.

Acknowledgements

We would like to acknowledge and show a heartfelt appreciation to our registry participants, medical advisory board members, and patient advisory board members for setting the FOP Registry on trajectory to achieve its critical research mission.

The FOP Registry is supported by generous funding from our sponsors: Blueprint Medicines, Clementia Pharmaceuticals, and Regeneron.